Test of Four Colon Cancer Risk-Scores in Formalin Fixed Paraffin Embedded Microarray Gene Expression Data

被引:27
作者
Di Narzo, Antonio F. [1 ]
Tejpar, Sabine [2 ,3 ]
Rossi, Simona [1 ]
Yan, Pu [4 ]
Popovici, Vlad [1 ]
Wirapati, Pratyaksha [1 ]
Budinska, Eva [1 ]
Xie, Tao [5 ]
Estrella, Heather [5 ]
Pavlicek, Adam [5 ]
Mao, Mao [5 ]
Martin, Eric [5 ]
Scott, Weinrich [5 ]
Bosman, Fred T. [4 ]
Roth, Arnaud [6 ,7 ]
Delorenzi, Mauro [1 ,8 ,9 ]
机构
[1] SIB, CH-1015 Lausanne, Switzerland
[2] Univ Hosp Gasthuisberg, Digest Oncol Unit, Leuven, Belgium
[3] Univ Hosp Gasthuisberg, Ctr Human Genet, Leuven, Belgium
[4] Univ Lausanne, Dept Pathol, CH-1015 Lausanne, Switzerland
[5] Pfizer Inc, Oncol Res Unit, Worldwide Res & Dev, La Jolla, CA USA
[6] Univ Hosp Geneva, Geneva, Switzerland
[7] SAKK Coordinat Ctr, Bern, Switzerland
[8] Univ Lausanne, Ludwig Ctr Canc Res, CH-1015 Lausanne, Switzerland
[9] Univ Lausanne, Dept Oncol, CH-1015 Lausanne, Switzerland
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2014年 / 106卷 / 10期
基金
瑞士国家科学基金会;
关键词
STAGE-II; COLORECTAL-CANCER; PREDICT RECURRENCE; ADJUVANT TREATMENT; POOR-PROGNOSIS; VALIDATION; TRIAL; ASSAY; PETACC-3; MARKER;
D O I
10.1093/jnci/dju247
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background Prognosis prediction for resected primary colon cancer is based on the T-stage Node Metastasis (TNM) staging system. We investigated if four well-documented gene expression risk scores can improve patient stratification. Methods Microarray-based versions of risk-scores were applied to a large independent cohort of 688 stage II/III tumors from the PETACC-3 trial. Prognostic value for relapse-free survival (RFS), survival after relapse (SAR), and overall survival (OS) was assessed by regression analysis. To assess improvement over a reference, prognostic model was assessed with the area under curve (AUC) of receiver operating characteristic (ROC) curves. All statistical tests were two-sided, except the AUC increase. Results All four risk scores (RSs) showed a statistically significant association (single-test, P < .0167) with OS or RFS in univariate models, but with HRs below 1.38 per interquartile range. Three scores were predictors of shorter RFS, one of shorter SAR. Each RS could only marginally improve an RFS or OS model with the known factors T-stage, N-stage, and microsatellite instability (MSI) status (AUC gains < 0.025 units). The pairwise interscore discordance was never high (maximal Spearman correlation = 0.563) A combined score showed a trend to higher prognostic value and higher AUC increase for OS (HR = 1.74, 95% confidence interval [CI] = 1.44 to 2.10, P < .001, AUC from 0.6918 to 0.7321) and RFS (HR = 1.56, 95% CI = 1.33 to 1.84, P < .001, AUC from 0.6723 to 0.6945) than any single score. Conclusions The four tested gene expression-based risk scores provide prognostic information but contribute only marginally to improving models based on established risk factors. A combination of the risk scores might provide more robust information. Predictors of RFS and SAR might need to be different.
引用
收藏
页数:8
相关论文
共 28 条
[1]
[Anonymous], 2010, R LANG ENV STAT COMP
[2]
Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer [J].
Arango, D ;
Laiho, P ;
Kokko, A ;
Alhopuro, P ;
Sammalkorpi, H ;
Salovaara, R ;
Nicorici, D ;
Hautaniemi, S ;
Alazzouzi, H ;
Salovaara, R ;
Nicorici, D ;
Hautaniemi, S ;
Alazzouzi, H ;
Mecklin, JP ;
Järvinen, H ;
Hemminki, A ;
Astola, J ;
Schwartz, S ;
Aaltonen, LA .
GASTROENTEROLOGY, 2005, 129 (03) :874-884
[3]
Stage II colon cancer prognosis prediction by tumor gene expression profiling [J].
Barrier, Alain ;
Boelle, Pierre-Yves ;
Roser, Francois ;
Gregg, Jennifer ;
Tse, Chantal ;
Brault, Didier ;
Lacaine, Francois ;
Houry, Sidney ;
Huguier, Michel ;
Franc, Brigitte ;
Flahault, Antoine ;
Lemoine, Antoinette ;
Dudoit, Sandrine .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4685-4691
[4]
American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[5]
Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial [J].
Bosman, Fred T. ;
Yan, Pu ;
Tejpar, Sabine ;
Fiocca, Roberto ;
Van Cutsem, Eric ;
Kennedy, Richard D. ;
Dietrich, Daniel ;
Roth, Arnaud .
CLINICAL CANCER RESEARCH, 2009, 15 (17) :5528-5533
[6]
Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer [J].
Ein-Dor, L ;
Zuk, O ;
Domany, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) :5923-5928
[7]
Molecular staging for survival prediction of colorectal cancer patients [J].
Eschrich, S ;
Yang, I ;
Bloom, G ;
Kwong, KY ;
Boulware, D ;
Cantor, A ;
Coppola, D ;
Kruhoffer, M ;
Aaltonen, L ;
Orntoft, TF ;
Quackenbush, J ;
Yeatman, TJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3526-3535
[8]
Concordance among gene-expression-based predictors for breast cancer [J].
Fan, Cheng ;
Oh, Daniel S. ;
Wessels, Lodewyk ;
Weigelt, Britta ;
Nuyten, Dimitry S. A. ;
Nobel, Andrew B. ;
van't Veer, Laura J. ;
Perou, Charles M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (06) :560-569
[9]
Validation Study of a Quantitative Multigene Reverse Transcriptase-Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer [J].
Gray, Richard G. ;
Quirke, Philip ;
Handley, Kelly ;
Lopatin, Margarita ;
Magill, Laura ;
Baehner, Frederick L. ;
Beaumont, Claire ;
Clark-Langone, Kim M. ;
Yoshizawa, Carl N. ;
Lee, Mark ;
Watson, Drew ;
Shak, Steven ;
Kerr, David J. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (35) :4611-4619
[10]
Revised TN Categorization for Colon Cancer Based on National Survival Outcomes Data [J].
Gunderson, Leonard L. ;
Jessup, John Milburn ;
Sargent, Daniel J. ;
Greene, Frederick L. ;
Stewart, Andrew K. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) :264-271